Cargando…

United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis

BACKGROUND: Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Schol, Jolien, Wauters, Lucas, Dickman, Ram, Drug, Vasile, Mulak, Agata, Serra, Jordi, Enck, Paul, Tack, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259275/
https://www.ncbi.nlm.nih.gov/pubmed/33939892
http://dx.doi.org/10.1002/ueg2.12060
_version_ 1783718642256445440
author Schol, Jolien
Wauters, Lucas
Dickman, Ram
Drug, Vasile
Mulak, Agata
Serra, Jordi
Enck, Paul
Tack, Jan
author_facet Schol, Jolien
Wauters, Lucas
Dickman, Ram
Drug, Vasile
Mulak, Agata
Serra, Jordi
Enck, Paul
Tack, Jan
author_sort Schol, Jolien
collection PubMed
description BACKGROUND: Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. METHODS: A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements. RESULTS: The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine‐2 antagonists and 5‐HT(4) receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long‐term prognosis of gastroparesis depends on the cause. CONCLUSIONS AND INFERENCES: A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis.
format Online
Article
Text
id pubmed-8259275
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82592752021-07-12 United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis Schol, Jolien Wauters, Lucas Dickman, Ram Drug, Vasile Mulak, Agata Serra, Jordi Enck, Paul Tack, Jan United European Gastroenterol J Neurogastroenterology BACKGROUND: Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. METHODS: A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements. RESULTS: The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine‐2 antagonists and 5‐HT(4) receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long‐term prognosis of gastroparesis depends on the cause. CONCLUSIONS AND INFERENCES: A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis. John Wiley and Sons Inc. 2021-05-03 /pmc/articles/PMC8259275/ /pubmed/33939892 http://dx.doi.org/10.1002/ueg2.12060 Text en © 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Neurogastroenterology
Schol, Jolien
Wauters, Lucas
Dickman, Ram
Drug, Vasile
Mulak, Agata
Serra, Jordi
Enck, Paul
Tack, Jan
United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis
title United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis
title_full United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis
title_fullStr United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis
title_full_unstemmed United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis
title_short United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis
title_sort united european gastroenterology (ueg) and european society for neurogastroenterology and motility (esnm) consensus on gastroparesis
topic Neurogastroenterology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259275/
https://www.ncbi.nlm.nih.gov/pubmed/33939892
http://dx.doi.org/10.1002/ueg2.12060
work_keys_str_mv AT scholjolien unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis
AT wauterslucas unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis
AT dickmanram unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis
AT drugvasile unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis
AT mulakagata unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis
AT serrajordi unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis
AT enckpaul unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis
AT tackjan unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis
AT unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis